Nomura has initiated coverage on Anthem Biosciences with a Buy rating and a ₹740 target, citing attractive valuations, strong CRDMO positio...

Aditya Sood of InCred Asset Management is bullish on India's market, expecting financials and domestic manufacturing to lead wealth creatio...

Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...

Avendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...

Indian markets initially stumbled but recovered following Trump's tariff announcement, with export-heavy sectors like textiles, pharma, and...

Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...

India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...

India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...

Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...

Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....

JM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India's CRDMO indus...

Quadria Capital is set to acquire a 10% stake in Aragen Life Sciences for about $100 million, valuing the Indian CRDMO at $1.2 billion. The...

Sai Life Sciences IPO: Sai Life Sciences' IPO saw full subscription on its second day, with a 1.25 times oversubscription. Retail investors...

The IPO of the contract research and manufacturing firm opened for subscription on Wednesday, achieving 84% overall subscription on the fir...

The issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...

Sai Life Sciences' unlisted shares traded at Rs 577 on Tuesday in the grey market, indicating a 5.1% premium over the IPO price band’s uppe...

India could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to wor...